Randox Biosciences: dedicated to advancing scientific discovery
Randox Biosciences: dedicated to advancing scientific discovery
Randox Laboratories is an international clinical diagnostic solutions company with over 35 years’ experience in the industry. Randox is a global market leader, providing revolutionary products for laboratories worldwide and is dedicated to improving health.
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. Spanning four key divisions; Life Sciences, Pharma Sciences, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use.
From initial cultivation of raw materials for assay development, through to providing companion diagnostics, custom and molecular based assays across a range of therapy areas; Randox Biosciences is a trusted partner supplying quality diagnostic solutions to the clinical, life science, pharmaceutical, research and biopharma industries. We specialise in supplying academic centres, genetics laboratories and the global biopharmaceutical industry with products tailored to their specific needs.
Randox Biosciences Research team encompasses a knowledgeable group of who are dedicated to assisting your research project to completion. Recently, the research team has expanded to include Business Development Executives in America to support academic centres of excellence achieve their potential while utilising our quality products. We are proud to welcome Rebecca Newburg who will be focusing her efforts on the US-Midwest market and Celestine Eshiet who will be working on the US -West Coast.
We cover five areas of research such as Sport and Exercise, Cardiovascular, Metabolic, Immunology and Oncology. These five areas include our Metabolic Syndrome Array 1 & 2, Cytokine Arrays and Cardiac Array including CK-MB, H-FABP, Myoglobin and Troponin.
If you work in an academic centre and are interested in our variety of arrays, analysers whether that be chemistry or immunoassay analysers, or our reagents or quality control please do not hesitate to contact us at info@randoxbiosciences.com.
Randox Biosciences: dedicated to advancing scientific discovery
Randox Laboratories is an international clinical diagnostic solutions company with over 35 years’ experience in the industry. Randox is a global market leader, providing revolutionary products for laboratories worldwide and is dedicated to improving health.
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. Spanning four key divisions; Life Sciences, Pharma Sciences, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use.
From initial cultivation of raw materials for assay development, through to providing companion diagnostics, custom and molecular based assays across a range of therapy areas; Randox Biosciences is a trusted partner supplying quality diagnostic solutions to the clinical, life science, pharmaceutical, research and biopharma industries. We specialise in supplying academic centres, genetics laboratories and the global biopharmaceutical industry with products tailored to their specific needs.
Randox Biosciences Research team encompasses a knowledgeable group of who are dedicated to assisting your research project to completion. Recently, the research team has expanded to include Business Development Executives in America to support academic centres of excellence achieve their potential while utilising our quality products. We are proud to welcome Rebecca Newburg who will be focusing her efforts on the US-Midwest market and Celestine Eshiet who will be working on the US -West Coast.
We cover five areas of research such as Sport and Exercise, Cardiovascular, Metabolic, Immunology and Oncology. These five areas include our Metabolic Syndrome Array 1 & 2, Cytokine Arrays and Cardiac Array including CK-MB, H-FABP, Myoglobin and Troponin.
If you work in an academic centre and are interested in our variety of arrays, analysers whether that be chemistry or immunoassay analysers, or our reagents or quality control please do not hesitate to contact us at info@randoxbiosciences.com.
Heart attack test H-FABP 12 times faster than current methods
As the supplier of a pioneering diagnostic able to assist with differentiating between coronary pain and non-cardiac chest pain, Randox Laboratories has this week welcomed news about the importance of introducing new innovations which can significantly improve patient outcomes.
Prioritising people presenting with a heart attack over those with non-cardiac chest pain is one of the biggest challenges A&E doctors face – there are around 200,000 heart attacks each year in the UK, but around 1 million people come to A&E with chest pains. According to a team from King’s College London, as reported by the BBC, a faster, more accurate diagnosis of whether chest pain is caused by a heart attack would save the health service millions of pounds each year by sending well patients home and freeing up beds. Yet current testing methods do not efficiently differentiate between high-risk patients and the estimated 80% of patients who are not having a heart attack.
Randox’s revolutionary test for Heart-Type Fatty Acid-Binding Protein (H-FABP) however, when combined with current testing, is able to rule out a heart attack for patients who present at A&E with chest pain which is caused by other conditions such as respiratory issues, meaning they may not need emergency admission.
When measured at the time a patient presents to A&E with chest pain, H-FABP enables doctors to triage patients suffering with a heart attack more efficiently than before.
Dr. Gary Smyth, Medical Director at Randox Laboratories, hopes that more efficient testing will become widely available so that doctors can identify and prioritise patients at risk;
“Despite the best efforts of our NHS colleagues, EDs across the UK are under tremendous pressure. In many cases people are presenting with chest pain but aren’t suffering from a heart attack, and given that current cardiac tests are not as sensitive as clinicians would like, these patients are being admitted unnecessarily, taking up beds and valuable resources.
“It is imperative that newer, faster tests are adopted because fundamentally this means saving lives.”
H-FABP is released into the bloodstream within 30 minutes of a heart attack, whereas people who are currently admitted to hospital with chest pains may have to wait several hours for test results. Even the latest heart attack test to be adopted by the NHS, troponin, can take up to six hours to provide confirmation.
H-FABP, conversely, is released from the heart during the early stages of a heart attack and because it is so small, it can be detected when the heart cells are being damaged, rather than at the stage when troponin would usually be detected – when cell death has already occurred. The test can also be used to identify people who are at high risk of heart attack in the near future.
Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;
“Research shows that patients who were troponin negative and therefore sent home from hospital, but who were positive for H-FABP, were at high risk of death – as high as a 20% chance of death that same year.
“If the H-FABP test was added to existing tests upon arrival at hospital, doctors could quickly and accurately rule out the 80% of chest pain patients who are not having a heart attack, allowing resources to be focused on those who are actually at high risk.”
For further information on H-FABP, please visit http://www.randox.com/h-fabp/, or contact the Randox PR team by phoning (0) 28 9442 2413 or emailing randoxpr@randox.com
Randox Reagents: Solving the Problem of Heart Attack Misdiagnosis
A report has today revealed that almost a third of patients in England and Wales are being given a misdiagnosis following a heart attack, following a study of 243 NHS hospitals, conducted by researchers at Leeds University.
Timely evaluation of patients with chest pain and subsequently suspected heart attack is a major challenge for hospitals around the world, with chest pain typically representing around 5% of all visits to the Emergency Department (ED) and 25% of ED admissions. One of the biggest challenges facing emergency doctors now is how to prioritise people presenting with chest pain – to primarily deal with those suffering from a heart attack, and to be able to move those who are not, to a different ward, to alleviate the pressures of the overrun A&E departments.
Responding to the escalating misdiagnosis crisis in emergency hospitals across the globe, scientists at Randox Laboratories in the UK have developed a test which could help clinicians rule out heart attacks in patients immediately upon arrival at hospital; allowing clinicians to accurately prioritise those who have truly suffered heart attacks.
This Randox test, for Heart-type fatty acid-binding protein (H-FABP), is a highly sensitive biomarker for use in the earlier diagnosis of patients with suspected Acute Myocardial Infarction (AMI), enabling faster “rule-in” and “rule-out”. H-FABP is detectable as early as 30 minutes after chest pain onset, significantly earlier than traditionally used biomarkers such as Troponin or CK-MB , which typically require 6-12 hours to reach detectable concentrations.
Put simply, given that H-FABP is released earlier than traditional biomarkers used in diagnosing a heart attack, an earlier diagnosis is achievable.
A succession of recent international clinical trials have demonstrated that by combining H-FABP, via this new laboratory assay, with the existing tests already used in hospitals for for Troponin I or Troponin T, the sensitivity and negative predictive value for ruling out AMIs is significantly improved.
Growing evidence indicates that even when one of the newer generation of “highly sensitive” Troponin assays is used, utilising the combination of Troponin and H-FABP is superior to Troponin alone.
The value of H-FABP is not just in positive diagnosis – but doctors are beginning to see it as a means of ‘ruling out heart attack’ when a patient presents at A&E with chest pain.
Please do get in touch if you would like to find out more about our H-FABP test, and how this can go a long way in solving the heart attack misdiagnosis crisis, by emailing reagents@randox.com
